The Helsinki University Central Hospital’s (HUCH) Comprehensive Cancer Center will receive the world’s first in-hospital BNCT equipment in 2018. The new technology has had promising results in the treatment of head and neck cancers.
The Hospital District of Helsinki and Uusimaa (HUS) and the American Neutron Therapeutics agreed in 2016 on the installation of the world’s first in-hospital BNCT equipment in Helsinki. The goal is to start treatments in HUS during 2018. BNCT, i.e. Boron Neutron Capture Therapy, is used to treat advanced head and neck cancers.
Neutron Therapeutics chose to partner with HUS because of the unique BNCT expertise in Helsinki.
We assisted HUS in the complex and lengthy agreement negotiations. The negotiations were held in a challenging environment because HUCH wasn’t the only potential candidate for the American parent company’s top unit. The collaboration agreement between HUS and Neutron Therapeutics is a major advancement for Finnish MedTech expertise and for the development of new cancer treatments.
“It’s great that HUS and Neutron Therapeutics reached an agreement to get the BNCT equipment in HUS. The negotiations were challenging because we were facing an entirely new kind of arrangement. Lexia’s professional expertise has been highly beneficial for us,” notes Administration Manager Jaana Vento from HUS.
The agreement and the rollout of BNCT treatment with a completely new type of equipment strengthen HUCH’s position globally as a prominent research and development center for cancer treatment. HUS will also become the leading research and development center for BNCT treatment.
HUS is the biggest actor in the healthcare sector in Finland with an annual turnover of about two billion euros, and it employs some 22,500 professionals.
